Glass House Brands (GLAS) Land & Improvements (2021 - 2024)
Glass House Brands (GLAS) posted quarterly Land & Improvements of $70.9 million for Q1 2024, little changed quarter-over-quarter from $70.9 million in Q4 2023.
Glass House Brands (GLAS) Land & Improvements (2021 - 2024) Analysis & Trends
Glass House Brands (GLAS) has reported Land & Improvements for 4 consecutive years, with $70.9 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Land & Improvements changed N/A year-over-year to $70.9 million; the TTM figure through Mar 2024 stood at $70.9 million (changed N/A YoY), while the FY2023 annual figure was $70.9 million, changed N/A from the prior year.
- Land & Improvements was little changed at $70.9 million in Q1 2024 per GLAS's latest filing, from $70.9 million in the prior quarter.
- Across five years, Land & Improvements topped out at $70.9 million in Q4 2023 and bottomed at $70.8 million in Q4 2021.
- Historically, Land & Improvements has averaged $70.8 million across 4 years, with a median of $70.8 million in 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Glass House Brands | 829.33 Mn | 810.78 Mn | 15.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 70.89 Mn |
| Dec 31, 2023 | 70.89 Mn |
| Mar 31, 2022 | 70.78 Mn |
| Dec 31, 2021 | 70.78 Mn |